Iovance Biotherapeutics, Inc.
NASDAQ Global MarketTotal Valuation
Iovance Biotherapeutics, Inc. carries a market capitalization of 3.92B, placing it among publicly traded companies globally. Its enterprise value stands at 1.82B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 3.92B |
| Enterprise Value | 1.82B |
Share Statistics
Iovance Biotherapeutics, Inc. currently has 452.97M shares outstanding.
| Shares Outstanding | 452.97M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 5.25, and the price-to-book ratio stands at 2.56.
| PE Ratio | N/A |
| PS Ratio | 5.25 |
| PB Ratio | 2.56 |
| P/TBV Ratio | 3.99 |
| P/FCF Ratio | -7.35 |
| P/OCF Ratio | -6.45 |
Enterprise Valuation
| EV / Sales | 5.59 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Iovance Biotherapeutics, Inc. maintains a current ratio of 4.35, meaning it holds 4.3x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 4.35 |
| Quick Ratio | 1.04 |
| Debt / Equity | 5.89 |
| Debt / EBITDA | -0.17 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -40.36 |
| Return on Assets (ROA) | -31.76 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 3.18 |
Taxes
| Income Tax | -4.26M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Iovance Biotherapeutics, Inc.'s stock has gained approximately 299.54545% over the past 52 weeks. The 50-day moving average sits at 5.81, while the 200-day moving average is 3.90.
| Beta (5Y) | N/A |
| 52-Week Price Change | 299.54545% |
| 50-Day Moving Average | 5.81 |
| 200-Day Moving Average | 3.90 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Iovance Biotherapeutics, Inc. generated 324.97M in revenue and converted that into -289.52M in net income, yielding earnings per share of -0.71. EBITDA reached -251.19M, while operating income came in at -296.17M.
| Revenue | 324.97M |
| Gross Profit | 157.29M |
| Operating Income | -296.17M |
| Pretax Income | -293.78M |
| Net Income | -289.52M |
| EBITDA | -251.19M |
| EBIT | -296.17M |
| Earnings Per Share (EPS) | -0.71 |
Balance Sheet
Iovance Biotherapeutics, Inc. holds 110.77M in cash and equivalents against 43.33M in total debt, resulting in a net debt position of -110.77M. Total book value stands at 736.04M, with working capital of 357.41M providing operational flexibility.
| Cash & Cash Equivalents | 110.77M |
| Total Debt | 43.33M |
| Net Debt | -110.77M |
| Equity (Book Value) | 736.04M |
| Book Value Per Share | 1.62 |
| Working Capital | 357.41M |
Cash Flow
Iovance Biotherapeutics, Inc. produced -264.18M in operating cash flow over the past twelve months. After subtracting -32.21M in capital expenditures, free cash flow totaled -296.39M - equivalent to -0.72 per share.
| Operating Cash Flow | -264.18M |
| Capital Expenditures | -32.21M |
| Free Cash Flow | -296.39M |
| FCF Per Share | -0.72 |
Margins
Iovance Biotherapeutics, Inc. operates with a gross margin of 48.40, reflecting its pricing power and cost economics. The operating margin of -91.14 and net profit margin of -89.09 provide insight into operational efficiency.
| Gross Margin | 48.40 |
| Operating Margin | -91.14 |
| Pretax Margin | -90.40 |
| Profit Margin | -89.09 |
| EBITDA Margin | -77.30 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -15.28 |
| FCF Yield | -13.60 |
Stock Splits
Iovance Biotherapeutics, Inc.'s most recent stock split took place on September 26, 2013 with a 100:1 split ratio.
| Last Split Date | 9/26/2013 |
| Split Ratio | 100:1 |
Scores
Iovance Biotherapeutics, Inc. posts an Altman Z-Score of -0.28, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -0.28 |